WHO. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020.
WHO. High burden to high impact. A targeted malaria response. Geneva: World Health Organization; 2019.
Greenwood B, Dicko A, Sagara I, Zongo I, Tinto H, Cairns M, et al. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malar J. 2017;16:182.
Miura K. Progress and prospects for blood-stage malaria vaccines. Expert Rev Vaccines. 2016;15:765–81.
Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011;365:1004–13.
Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, et al. Human vaccination against RH5 induces neutralising antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. 2017;2:e96381.
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, et al. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention. BMJ Open. 2020;10:e035433.
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, et al. Seasonal vaccination with the RTS,S/AS01E malaria vaccine with or without seasonal malaria chemoprevention. N Engl J Med. 2020. https://doi.org/10.1136/bmjopen-2019-035433.
Adepoju P. RTS,S malaria vaccine pilots in three African Countries. Lancet. 2019;393:1685.
Rostenberg M, McCall M, Hopman J, Wiersma J, Luty AJF, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361:468–77.
Mwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. 2021;595:289–94.
Aponte JJ, Schellenberg D, Egan E, Breckenridge A, Carneiro I, Critchley J, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomized, placebo-controlled trials. Lancet. 2009;374:1533–42.
Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomized, double-blind, placebo-controlled trial. Lancet. 2009;374:1521–32.
Crawley J, Sismanidis C, Goodman T, Milligan P, WHO Advisory Committee on serological responses to vaccines used in the Expanded Programme on Immunization in infants receiving Intermittent Preventive Treatment for malaria. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomized controlled trials. Lancet. 2012;380:1001–10.
Maiga OM, Kayentao K, Traoré BT, Diallo M, Ongoiba A, Doumtabé D, et al. Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in Mali: a randomized controlled trial. Clin Infect Dis. 2011;53:215–23.
Van Eijk AM, Larsen DA, Kayenatao K, Koshy G, Slaughter DEC, Roper C, et al. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:546–56.
Desai M, Gutman J, L’Lanziva A, Otieno K, Juma E, Kariuki S, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015;356:2507–19.
Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016;374:928–39.
Kazubi R, Ochieng T, Kakuru A, Jagannathan P, Nakalembe M, Ruel T, et al. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superioritty trial. Lancet. 2019;393:1428–39.
Desai M, Hill J, Fernandes S, Walker P, Pell C, Gutman J, et al. Prevention of malaria in pregnancy. Lancet Infect Dis. 2018;18:e119–32.
Roh ME, Kuile FOT, Rerolle F, Glymour MM, Shiboski S, Gosling R, et al. Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. Lancet Glob Health. 2020;8:e942–53.
Mordmüller B, Sulyok M, Egger-Adam D, Resende M, de Jongh WA, Jensen MH, et al. First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria. Clin Infect Dis. 2019;69:1509–16.
Sirima SB, Richert L, Chene A, Konate AT, Campion C, Dechavanna S, et al. PRIMVAC vaccine adjuvanted with alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis. 2020;20:585–97.
Healy SA, Fried M, Richie T, Bok K, Little M, August A, et al. Malaria vaccine trials in pregnant women: an imperative without precedent. Vaccine. 2019;37:763–70.
Zucker JR, Lackritz EM, Ruebush TK II, Hightower AW, Adungosi JE, Were BO, et al. Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens. Am J Trop Med Hyg. 1996;55:655–60.
Bojang KA, Palmer A, Boele van Hensbroek M, Banya WAS, Greenwood BM. Management of severe malarial anaemia in Gambian children. Trans R Soc Trop Med Hyg. 1997;91:557–61.
Bojang KA, Milligan PJ, Conway DJ, Sisay-Joof F, Jallow M, Nwakanma DC, et al. Prevention of the recurrence of anaemia in Gambian children following discharge from hospital. PLoS ONE. 2010;5:e1122.7.
Phiri K, Esan M, van Hensbroek MB, Khairallah C, Faragher B, ter Kuile FO. Intermittent preventive therapy for malaria with monthly artemether-lumefantrine for the post-discharge management of severe anaemia in children aged 4–59 months in southern Malawi: a multicentre, randomised, placebo-controlled trial. Lancet Infect Dis. 2012;12:191–200.
Kwambai T, Dhabangi A, Idro R, Opoka R, Watson V, Kariuki S, et al. Malaria chemoprevention for the post-discharge management of severe anemia. N Engl J Med. 2020;383:2242–54.
Frimpong A, Thiam LG, Ako-Boham B, Owusu EDA, Sdjei GO. Safety and effectiveness of antimalarial therapy in sickle cell diseases: a systematic review and network meta-analysis. BMC Infect Dis. 2018;18:650.
Billingsley PF, Maas CD, Olutu A, Schwabe C, Garcia GA, Rivas MR, et al. The Equatoguinean malaria vaccine initiative: from the launching of a clinical research platform to malaria elimination planning in Central West Africa. Am J Trop Med Hyg. 2020;103:947–54.
von Seidlein L, Hanboonkunupakarn B, Jittamala P, Pongsuwan P, Chotivanich K, Tarning J, et al. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS, S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. Hum Vaccin Immunother. 2020;16:33–41.
Gaudinski MR, Berkowitz NM, Idris AH, Coates EE, Holman LA, Mendoza F, et al. A monoclonal antibody for malaria prevention. N Engl J Med. 2021;385:803-14.